Kartik Raghupathi Selected Research

Gold

10/2013

Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kartik Raghupathi Research Topics

Disease

4	Multiple Sclerosis 11/2019 - 09/2012
2	Asthma (Bronchial Asthma) 01/2022 - 01/2020
2	Relapsing-Remitting Multiple Sclerosis 10/2013 - 09/2012
1	Hypoxia (Hypoxemia) 01/2022
1	Inflammation (Inflammations) 01/2020
1	Atrioventricular Block 11/2019
1	Disease Progression 11/2019
1	Opportunistic Infections (Opportunistic Infection) 11/2019
1	Flushing 09/2012

Drug/Important Bio-Agent (IBA)

2	prostaglandin D2 receptorIBA 01/2022 - 01/2020
2	ozanimodIBA 11/2019 - 11/2019
2	Interferon beta-1a FDA Link 11/2019 - 11/2019
2	GadoliniumIBA 11/2019 - 11/2019
2	Glatiramer Acetate (Copaxone)FDA Link 10/2013 - 09/2012
2	Dimethyl FumarateIBA 10/2013 - 09/2012
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	ORALIT (ORS)IBA 01/2022
1	ProstaglandinsIBA 01/2022
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	GoldIBA 10/2013
1	InterferonsIBA 09/2012

Therapy/Procedure

2	Therapeutics 11/2019 - 11/2019